Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer

Author:

Han James1ORCID,Zakeri Kaveh1ORCID,Raab Gabriel1,Hesse Jennifer1,Shamseddine Achraf1,Chen Linda1,Yu Yao1,Kang Jung Julie1,McBride Sean M.1,Riaz Nadeem1,Tsai C. Jillian1ORCID,Gelblum Daphna1,Sherman Eric J.2,Wong Richard J.3,Michel Loren2,Lee Nancy Y.1

Affiliation:

1. Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York USA

2. Department of Medicine Memorial Sloan Kettering Cancer Center New York New York USA

3. Department of Surgery Memorial Sloan Kettering Cancer Center New York New York USA

Abstract

AbstractBackgroundWe report the outcomes of cisplatin‐ineligible HNSCC patients treated with definitive chemoradiation and concurrent carboplatin and paclitaxel.Materials and MethodsWe included consecutive HNSCC patients treated from 2013 to 2021 that received definitive chemoradiation with carboplatin and paclitaxel. Locoregional recurrences (LRR) and distant metastases (DM) were estimated using cumulative incidence functions. Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier methods.ResultsSixty‐five patients were identified with median age of 71 years (range 44–85). Median radiation dose was 70 Gy and the median doses of carboplatin and paclitaxel were AUC 1 and 40 mg/m2, respectively. At a median follow‐up of 29 (range 5–91) months, the 2‐year rates of LRR, DM, PFS, and OS were 8.8%, 9.4%, 72.2%, and 88.7%, respectively. In total, there were 5 LRR, 7 DM, and 12 deaths.ConclusionsChemoradiation with carboplatin and paclitaxel is an excellent option for cisplatin‐ineligible HNSCC patients.

Publisher

Wiley

Subject

Otorhinolaryngology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3